Travel

[키워드] 1:1 48 hour 48 hours Activation Administered adverse event African age allergy analyzed Angola Antiviral approved ARMS Barcelona baseline blinded block Cerebrovascular disease chain chest X-ray childbearing chronic clinical care clinical trial co-morbidity conducted contraceptive method control group coronary disease cough country COVID-19 COVID-19 disease COVID-19 patient criteria Critical current CYP3A4 death detectable determine diagnosed with COVID-19 disease dissemination dose double-blind drug early treatment Efficacy element Endemic EudraCT excluded eye Factor Fever flow cytometry Follow-up visit Frequency Gabon global health groups history home visit Identified IgA IgA level IgG IgM immune response Immunity immunology immunomodulatory IMPROVE in vivo Infection Inflammatory inhibitor interfere investigator involved Isolation Ivermectin laboratory parameter Loa loa magnitude marker median Nasopharyngeal swab nasopharyngeal swab PCR negative neoplasm Nigeria no risk number objective outcome participant Patient Patient care patients PCR PCR cycle physical Placebo placebo group placebo-controlled Pneumonia positive positive SARS-CoV-2 PCR post-menopausal Potential pregnancy test pregnant women progression proportion protocol public health pulmonary random randomised randomised controlled trial randomization randomization list Randomized Rapid diagnostic test reaction receive recent recruited reduce Registered renal resident risk Ritonavir Safe Sample size SARS-CoV-2 SARS-CoV-2 RNA SARS-CoV-2-specific T cell secondary sequence Seroconversion severe disease severity single center single dose Spain status Study protocol subject submitted surgical Symptom symptom onset the patient the SARS-CoV-2 threshold transcriptomics Transmission transmission-blocking Travel treated patient treated patients Treatment treatment group Trial unblinding Viral load virus vulnerable population website with mild disease women
[DOI] 10.1186/s13063-020-04421-z PMC 바로가기 [Article Type] Letter